Obesity Drugs Should Be Covered Under Part D, Drug Firms Urge CMS
Executive Summary
CMS should withdraw its current guidance barring Medicare Part D reimbursement of obesity drugs, the Pharmaceutical Research and Manufacturers of America and the Biotechnology Industry Organization advise in separate July 24 comments to the agency
You may also be interested in...
Zafgen Finds Plentiful Funding in Slimmed Down Obesity Market
The obesity-foucsed start-up Zafgen has emerged from stealth mode. Taking the reins as CEO is Thomas Hughes, PhD, former VP and global head of cardiovascular and metabolic disease at Novartis. With $22 million in funding from Atlas Venture and Third Rock Ventures, the company is well capitalized to drive its lead molecules into the clinic.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.